单位:[1]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Thorac Surg,Canc Hosp, Beijing 100730, Peoples R China[2]Chinese Acad Med Sci, Key Lab Minimally Invas Therapy Res Lung Canc, Beijing, Peoples R China[3]Nanjing Geneseeq Technol Inc, Geneseeq Res Inst, Nanjing, Jiangsu, Peoples R China[4]Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Thorac Surg, Beijing, Peoples R China[5]China Japan Friendship Hosp, Dept Thorac Surg, Beijing, Peoples R China[6]Nanjing Med Univ, Sch Publ Hlth, Nanjing, Jiangsu, Peoples R China
Background Early diagnosis benefits lung cancer patients with higher survival, but most patients are diagnosed after metastasis. Although cell-free DNA (cfDNA) analysis holds promise, its sensitivity for detecting early-stage lung cancer is unsatisfying. We leveraged cfDNA fragmentomics to develop a predictive model for invasive stage I lung adenocarcinoma (LUAD). Methods 292 stage I LUAD patients from three medical centers were included together with 230 healthy controls whose plasma cfDNA samples were profiled by whole-genome sequencing (WGS). Multiple cfDNA fragmentomic motif features and machine learning models were compared in the training cohort to select the best model. Model performance was assessed in the internal and external validation cohorts and an additional dataset. Findings A logistic regression model using the 6bp-breakpoint-motif feature was selected. It yielded 98.0% sensitivity and 94.7% specificity in the internal validation cohort [Area Under the Curve (AUC): 0.985], while 92.5% sensitivity and 90.0% specificity were achieved in the external validation cohort (AUC: 0.954). It is sensitive for early stage (100% sensitivity for minimally invasive adenocarcinoma, MIA) and <1 cm (92.9%-97.7% sensitivity) tumors. The predictive power remained high when reducing sequencing depth to 0.5x (AUC: 0.977 and 0.931 for internal and external cohorts). Interpretation Here we have established a cfDNA breakpoint motif-based model for detecting early-stage LUAD, including MIA and very small-size tumors, shedding light on early cancer diagnosis in clinical practice. Copyright (C) 2022 The Author(s). Published by Elsevier B.V.
基金:
National Key R&D Program of China; National Natural Science Foundation of China; CAMS Initiative for Innovative Medicine; Special Research Fund for Central Universities, Peking Union Medical College; Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences; Beijing Hope Run Special Fund of Cancer Foundation of China
第一作者单位:[1]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Thorac Surg,Canc Hosp, Beijing 100730, Peoples R China[2]Chinese Acad Med Sci, Key Lab Minimally Invas Therapy Res Lung Canc, Beijing, Peoples R China
通讯作者:
通讯机构:[1]Chinese Acad Med Sci & Peking Union Med Coll, Natl Clin Res Ctr Canc, Natl Canc Ctr, Dept Thorac Surg,Canc Hosp, Beijing 100730, Peoples R China[2]Chinese Acad Med Sci, Key Lab Minimally Invas Therapy Res Lung Canc, Beijing, Peoples R China[*1]Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China
推荐引用方式(GB/T 7714):
Guo Wei,Chen Xin,Liu Rui,et al.Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling[J].EBIOMEDICINE.2022,81:doi:10.1016/j.ebiom.2022.104131.
APA:
Guo, Wei,Chen, Xin,Liu, Rui,Liang, Naixin,Ma, Qianli...&He, Jie.(2022).Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling.EBIOMEDICINE,81,
MLA:
Guo, Wei,et al."Sensitive detection of stage I lung adenocarcinoma using plasma cell-free DNA breakpoint motif profiling".EBIOMEDICINE 81.(2022)